High-throughput matrix screening in ovarian cancer cells identifies synergistic drug combinations with the second mitochondrial-derived activator of caspases (SMAC) mimetic birinapant (TL32711)

Bunch, Kristen

517
High-throughput matrix screening in ovarian cancer cells identifies synergistic drug combinations with the second mitochondrial-derived activator of caspases (SMAC) mimetic birinapant (TL32711)

Sunday, March 29, 2015: 7:00 AM

Salon C-D (Hilton Chicago)

K. P. Bunch¹, I. S. Goldlust², C. J. Thomas² and C. M. Annunziata¹
¹National Cancer Institute, Bethesda, MD, ²National Center for Advancing Translational Sciences, Rockville, MD

2015 Annual Meeting on Women's Cancer®

March 26 - 31, 2015

Navigation

517
High-throughput matrix screening in ovarian cancer cells identifies synergistic drug combinations with the second mitochondrial-derived activator of caspases (SMAC) mimetic birinapant (TL32711)

517 High-throughput matrix screening in ovarian cancer cells identifies synergistic drug combinations with the second mitochondrial-derived activator of caspases (SMAC) mimetic birinapant (TL32711)

517
High-throughput matrix screening in ovarian cancer cells identifies synergistic drug combinations with the second mitochondrial-derived activator of caspases (SMAC) mimetic birinapant (TL32711)